2020. Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2). SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s96. DOI:https://doi.org/10.25251/skin.4.supp.96.